Search Results - "Shenkier, Tamara N"

International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: Altered Utility in the Modern Era by MOCCIA, Alden A, DONALDSON, Jane, CONNORS, Joseph M, SEHN, Laurie H, CHHANABHAI, Mukesh, HOSKINS, Paul J, KLASA, Richard J, SAVAGE, Kerry J, SHENKIER, Tamara N, SLACK, Graham W, SKINNIDER, Brian, GASCOYNE, Randy D

“…The International Prognostic Score (IPS) is the most widely used risk stratification index for Hodgkin's lymphoma (HL). It is based on patients treated before…”
Get full text

Population-Based Analysis of Incidence and Outcome of Transformed Non-Hodgkin's Lymphoma by AL-TOURAH, Abdulwahab J, GILL, Karamjit K, CHHANABHAI, Mukesh, HOSKINS, Paul J, KLASA, Richard J, SAVAGE, Kerry J, SEHN, Laurie H, SHENKIER, Tamara N, GASCOYNE, Randy D, CONNORS, Joseph M

“…To assess the incidence and predictive factors for development of transformed lymphoma in a population-based series of patients with follicular lymphoma (FL)…”
Get full text

Effect of Letrozole Versus Placebo on Bone Mineral Density in Women With Primary Breast Cancer Completing 5 or More Years of Adjuvant Tamoxifen: A Companion Study to NCIC CTG MA.17 by Perez, Edith A, Josse, Robert G, Pritchard, Kathleen I, Ingle, James N, Martino, Silvana, Findlay, Brian P, Shenkier, Tamara N, Tozer, Richard G, Palmer, Michael J, Shepherd, Lois E, Liu, Shifang, Tu, Dongsheng, Goss, Paul E

“…Aromatase inhibition depletes estrogen levels and may be associated with accelerated bone resorption. The National Cancer Institute of Canada Clinical Trials…”
Get full text

Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report by Doolittle, Nancy D., Abrey, Lauren E., Shenkier, Tamara N., Tali, Siegal, Bromberg, Jacoline E.C., Neuwelt, Edward A., Soussain, Carole, Jahnke, Kristoph, Johnston, Patrick, Illerhaus, Gerald, Schiff, David, Batchelor, Tracy, Montoto, Silvia, Kraemer, Dale F., Zucca, Emanuele

“…Isolated central nervous system (CNS) relapse involving the brain parenchyma is a rare complication of systemic non-Hodgkin lymphoma. We retrospectively…”
Get full text

Molecular features of a large cohort of primary central nervous system lymphoma using tissue microarray by Villa, Diego, Tan, King L., Steidl, Christian, Ben-Neriah, Susana, Al Moosawi, Muntadhar, Shenkier, Tamara N., Connors, Joseph M., Sehn, Laurie H., Savage, Kerry J., Scott, David W., Gascoyne, Randy D., Slack, Graham W.

“…The objective of this study was to evaluate the distribution and prognostic impact of a broad range of molecular attributes in a large cohort of…”
Get full text

Primary CNS Lymphoma of T-Cell Origin: A Descriptive Analysis From the International Primary CNS Lymphoma Collaborative Group by Shenkier, Tamara N, Blay, Jean-Yves, O'Neill, Brian Patrick, Poortmans, Philip, Thiel, Eckhard, Jahnke, Kristoph, Abrey, Lauren E, Neuwelt, Edward, Tsang, Richard, Batchelor, Tracy, Harris, Nancy, Ferreri, Andrés J M, Ponzoni, Maurilio, O'Brien, Peter, Rubenstein, James, Connors, Joseph M

“…To describe the demographic and tumor related characteristics and outcomes for patients with primary T-cell CNS lymphoma (TPCNSL). A retrospective series of…”
Get full text

International study on low-grade primary central nervous system lymphoma by Jahnke, Kristoph, Korfel, Agnieszka, O'Neill, Brian Patrick, Blay, Jean-Yves, Abrey, Lauren E., Martus, Peter, Poortmans, Philip M. P., Shenkier, Tamara N., Batchelor, Tracy T., Neuwelt, Edward A., Raizer, Jeffrey J., Schiff, David, Pels, Hendrik, Herrlinger, Ulrich, Stein, Harald, Thiel, Eckhard

“…Objective The aim of this study was to characterize the clinical presentation, course, and outcome of low‐grade primary central nervous system lymphoma…”
Get full text

Rituximab with high‐dose methotrexate in primary central nervous system lymphoma by Kansara, Roopesh, Shenkier, Tamara N., Connors, Joseph M., Sehn, Laurie H., Savage, Kerry J., Gerrie, Alina S., Villa, Diego

“…The addition of rituximab (R) to chemotherapy improves outcomes in patients with systemic B‐cell non‐Hodgkin lymphomas, but the impact in patients with primary…”
Get full text

Outcomes in splenic marginal zone lymphoma: analysis of 107 patients treated in British Columbia by Xing, Katharine H., Kahlon, Amrit, Skinnider, Brian F., Connors, Joseph M., Gascoyne, Randy D., Sehn, Laurie H., Savage, Kerry J., Slack, Graham W., Shenkier, Tamara N., Klasa, Richard, Gerrie, Alina S., Villa, Diego

“…Summary Splenic marginal zone lymphoma (SMZL) accounts for less than 2% of all non‐Hodgkin lymphomas. We identified 107 cases diagnosed with SMZL between 1985…”
Get full text

Long-term outcomes of R-CEOP show curative potential in patients with DLBCL and a contraindication to anthracyclines by Moccia, Alden A., Schaff, Kimberly, Freeman, Ciara, Hoskins, Paul J., Klasa, Richard J., Savage, Kerry J., Shenkier, Tamara N., Gascoyne, Randy D., Connors, Joseph M., Sehn, Laurie H.

“…Doxorubicin plays an integral role in the treatment of patients with diffuse large B-cell lymphoma (DLBCL) but can be associated with significant toxicity…”
Get full text

Prognostic and Predictive Value of Tumor Vascular Endothelial Growth Factor Gene Amplification in Metastatic Breast Cancer Treated with Paclitaxel with and without Bevacizumab; Results from ECOG 2100 Trial by SCHNEIDER, Bryan P, GRAY, Robert J, COBLEIGH, Melody A, PEREZ, Edith A, SHENKIER, Tamara N, NIELSEN, Kirsten Vang, MÜLLER, Sven, THOR, Ann, SLEDGE, George W, SPARANO, Joseph A, DAVIDSON, Nancy E, BADVE, Sunil S, RADOVICH, Milan, FEI SHEN, VANCE, Gail, LANG LI, GUANGLONG JIANG, MILLER, Kathy D, GRALOW, Julie R, DICKLER, Maura N

“…Clinically validated biomarkers for anti-angiogenesis agents are not available. We have previously reported associations between candidate VEGFA…”
Get full text

Impact of time from diagnosis to initiation of curative-intent chemotherapy on clinical outcomes in patients with classical Hodgkin lymphoma by Brooks, Edward G, Connors, Joseph M, Sehn, Laurie H, Gascoyne, Randy D, Savage, Kerry J, Shenkier, Tamara N, Klasa, Richard, Gerrie, Alina S, Skinnider, Brian, Slack, Graham W, Villa, Diego

“…The impact of treatment delays on outcomes in Hodgkin lymphoma (HL) is currently unknown. Time from definitive histologic diagnosis to first ABVD treatment…”
Get full text

Unusual variants of primary central nervous system lymphoma by Shenkier, Tamara N

“…Rare variants of primary central nervous system lymphoma (PCNSL) include unusual sites of presentation (eg, neurolymphomatosis and primary leptomeningeal…”
Get more information

Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: An 18-year experience from the British Columbia cancer agency by SHENKIER, Tamara N, VOSS, Nicholas, FAIREY, Randall, GASCOYNE, Randy D, HOSKINS, Paul, KLASA, Richard, KLIMO, Paul, O'REILLY, Susan E, SUTCLIFFE, Simon, CONNORS, Joseph M

“…To evaluate clinical outcome of patients with limited-stage diffuse large-cell lymphoma (DLCL) treated with three cycles of chemotherapy followed by…”
Get full text

The treatment of primary central nervous system lymphoma in 122 immunocompetent patients: A population-based study of successively treated cohorts from the British Columbia cancer agency by SHENKIER, Tamara N, VOSS, Nicholas, SEHN, Laurie, CONNORS, Joseph M, CHHANABHAI, Mukesh, FAIREY, Randall, GASCOYNE, Randy D, HOSKINS, Paul, KLASA, Richard, MORRIS, James, O'REILLY, Susan E, PICKLES, Tom

Get full text

A Phase II Trial of a Neoadjuvant Platinum Regimen for Locally Advanced Breast Cancer: Pathologic Response, Long-Term Follow-up, and Correlation With Biomarkers by Yerushalmi, Rinat, Hayes, Malcolm M, Gelmon, Karen A, Chia, Stephen, Bajdik, Chris, Norris, Brian, Speers, Caroline, Hassell, Patricia, O'Reilly, Susan E, Allan, Sharon, Shenkier, Tamara N

“…Abstract Purpose The purpose of this study is to determine the response, tolerability, and long-term outcome of a neoadjuvant platinum-containing regimen for…”
Get full text

Improved Outcome of Human Immunodeficiency Virus-Associated Plasmablastic Lymphoma of the Oral Cavity in the Era of Highly Active Antiretroviral Therapy: A Report of Two Cases by Lester, Richard, Li, Charles H, Phillips, Peter, Shenkier, Tamara N, Gascoyne, Randy D, Galbraith, Paul F, Vickars, Linda M, Leitch, Heather A

“…Plasmablastic lymphoma (PBL) is a recently described type of non-Hodgkin's lymphoma (NHL) that occurs in up to 3% of patients with HIV infection. Although the…”
Get full text

The treatment of primary central nervous system lymphoma in 122 immunocompetent patients by Shenkier, Tamara N., Voss, Nicholas, Chhanabhai, Mukesh, Fairey, Randall, Gascoyne, Randy D., Hoskins, Paul, Klasa, Richard, Morris, James, O'Reilly, Susan E., Pickles, Tom, Sehn, Laurie, Connors, Joseph M.

“…BACKGROUND The objective of this study was to evaluate the clinical outcome of a population‐based cohort of immunocompetent patients with primary central…”
Get full text

Advanced Stage Classical Hodgkin Lymphoma Patients with a Negative PET-Scan Following Treatment with ABVD Have Excellent Outcomes without the Need for Consolidative Radiotherapy Regardless of Disease Bulk at Presentation by Savage, Kerry J., Connors, Joseph M., Villa, Diego R, Hapgood, Greg, Gerrie, Alina S, Shenkier, Tamara N, Scott, David W, Gascoyne, Randy D., Benard, Francois, Morris, James, Pickles, Tom, Parsons, Christina, Wilson, Don, Sehn, Laurie H.

“…Background: Consolidative radiotherapy (RT) is frequently administered to patients (pts) with classical Hodgkin lymphoma (CHL) that have bulky disease at…”
Get full text

Brief Chemotherapy and Involved-Region Irradiation for Limited-Stage Diffuse Large-Cell Lymphoma: An 18-Year Experience From the British Columbia Cancer Agency by Shenkier, T. N.

Get full text